Billing Codes, National Drug Codes, and Immunization Registry Codes for VAXELIS® (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine)¹

Included are lists of codes that may be relevant for VAXELIS and other selected combination vaccines and their administration. This information is current as of October 2023. The information provided here is compiled from sources believed to be accurate, but Merck makes no representation that it is accurate. Consult the relevant manual and/or other guidelines for a description of each code to determine the appropriateness of a particular code and for information on additional codes. This information is subject to change. Merck cautions that payer coding requirements vary and can frequently change, so it is important to regularly check with each payer as to payer-specific requirements.

You are solely responsible for determining the appropriate codes and for any action you take in billing. The information provided here is not intended to be definitive or exhaustive and is not intended to replace the guidance of a qualified professional advisor. Merck and its agents make no warranties or guarantees, expressed or implied, concerning the accuracy or appropriateness of this information for your particular use given the frequent changes in public and private payer billing. The use of this information does not guarantee payment or that any payment received will cover your costs. Diagnosis codes should be selected only by a health care professional. Furthermore, the total number of administration codes in this resource is not intended to represent any financial benefit or advantage of using VAXELIS.

Indication

• VAXELIS is a vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b (Hib). VAXELIS is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday).

Important Safety Information

- Do not administer VAXELIS to anyone with a history of severe allergic reaction to a previous dose of VAXELIS, any ingredient of VAXELIS, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis B vaccine, or Hib vaccine.
- Do not administer VAXELIS to anyone with a history of encephalopathy within 7 days of a pertussis-containing vaccine with no other identifiable cause.

Important Safety Information continues on next page.



VAXELIS® (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine)¹

Common CPT^a Codes for Administration of VAXELIS, with counseling by physician or other qualified HCP (90460, 90461)^b

VAXELIS Product Code	2 Months	4 Months	6 Months	Total	
90697 VAXELIS, for intramuscular use	1	1	1	3	
Administration of Vaccine	2 Months	4 Months	6 Months	Total	
90460 Immunization administration (IA) through 18 years of age via any route of administration, with counseling by physician or other qualified HCP; first or only component of each vaccine or toxoid administered (Bill 1 unit for the first component of VAXELIS)	1	1	1	3	18
90461 Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified HCP; each additional vaccine or toxoid component administered (list separately in addition to code for primary procedure) (Bill 5 units; 1 unit for each additional component within VAXELIS)	5	5	5	15	Codes fo

Important Safety Information (continued)

- Do not administer VAXELIS to anyone with a history of progressive neurologic disorder until a treatment regimen has been established and the condition has stabilized.
- Carefully consider benefits and risks before administering VAXELIS to persons with a history of: fever ≥40.5°C (≥105°F), hypotonic-hyporesponsive episode (HHE), or persistent, inconsolable crying lasting ≥3 hours within 48 hours after a previous pertussis-containing vaccine; and/or seizures within 3 days after a previous pertussis-containing vaccine.

Important Safety Information continues on next page.

The use of this information does not guarantee payment or that payment received will cover your costs. Diagnosis codes should be selected only by a health care professional.



^aCurrent Procedural Terminology (CPT) is a registered trademark of the American Medical Association.


^bAdministration codes 90460 & 90461 are applicable only when the age of the patient and qualified counseling requirements that are defined within the code descriptors are met.

CPT, Current Procedural Terminology; HCP, health care provider.

VAXELIS® (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine)¹

Common CPT^a Codes for Administration of VAXELIS, without counseling by physician or other qualified HCP (90471, 90472)

If VAXELIS is administered first during a child's visit:



If VAXELIS is administered subsequent to other vaccine(s) during a child's visit:

VAXELIS Product Code	2M	4M	6M	Total	
90697 VAXELIS, for intramuscular use	1	1	1	3	
Administration of Vaccine	2M	4M	6M	Total	
90472 Immunization administration; each additional injected vaccine (single or combination vaccine/toxoid) (Assuming VAXELIS is administered subsequent to other vaccine[s] during child's visit, bill 1 unit)	1	1	1	3	3 Codes for Administration

Important Safety Information (continued)

- If Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the risk for Guillain-Barré syndrome may be increased following VAXELIS.
- Apnea following intramuscular vaccination has been observed in some infants born prematurely. Consider the individual infant's medical status and potential benefits and possible risks of intramuscular vaccination in deciding when to administer VAXELIS to an infant born prematurely.

Important Safety Information continues on next page.

^aCurrent Procedural Terminology (CPT) is a registered trademark of the American Medical Association.

CPT, Current Procedural Terminology; M, months.

The use of this information does not guarantee payment or that payment received will cover your costs. Diagnosis codes should be selected only by a health care professional.



Billing Code

Common ICD-10-CM Code ²	Description
Z23 °	Encounter for immunization

National Drug Codes and Immunization Registry Codes

Supplied Packages	NDC Unit of Use	NDC Carton
10 single-dose vials	N463361024358 ML0.5	N463361024310 ML0.5
10 single-dose prefilled syringes	N463361024388 ML0.5	N463361024315 ML0.5
CVX Code ³	146	
MVX Code ³	MSP	

Codes for Administration⁴

If a vaccination is the only service provided, a visit should not be billed. If a vaccination is provided during a visit with other services, consult payer-specific requirements.

Important Safety Information (continued)

- Vaccination with VAXELIS may not protect all individuals.
- The solicited adverse reactions 0-5 days following any dose were irritability (≥55%), crying (≥45%), injection site pain (≥44%), somnolence (≥40%), injection site erythema (≥25%), decreased appetite (≥23%), fever ≥38.0°C (≥19%), injection site swelling (≥18%), and vomiting (≥9%).
- The 3-dose immunization series consists of a 0.5 mL intramuscular injection, administered at 2, 4, and 6 months of age.
- A 3-dose series of VAXELIS does not constitute a primary immunization series against pertussis; an additional dose of pertussis-containing vaccine is needed to complete the primary series.

Before administering VAXELIS, please read the accompanying <u>Prescribing Information</u>. The <u>Patient Information</u> also is available.

^a Z23 is reported for all vaccine-related encounters for all vaccines given, and in addition to any health exam ICD-10-CM codes.
The use of this information does not guarantee payment or that payment received will cover your costs. Diagnosis codes should be selected only by a health care professional. ICD-10-CM, International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Clinical Modification; NDC, National Drug Code.
Please note: The NDCs above are the billable NDCs that appear on the carton and the unit of use, when NDC is required by the payer.
CVX Code indicates the product used in a vaccination; MVX Code indicates the manufacturer of a vaccine.

References: 1. American Academy of Pediatrics. Coding for pediatrics 2023: a manual for pediatric documentation and payment. Appendix III: vaccine products: commonly administered pediatric vaccines. 2023. Accessed October 3, 2023. https://publications.aap.org/aapbooks/book/729/chapter-abstract/10990279/Vaccine-Products-Commonly-Administered-Pediatric 2. Centers for Disease Control and Prevention. ICD-10-CM tabular list of diseases and injuries 2023. Last modified January 11, 2023. Accessed October 3, 2023. https://www.cms.gov/medicare/icd-10/2023-icd-10-cm 3. Centers for Disease Control and Prevention. IIS: HL7 standard code set: Mapping product names to CVX and MVX. Last reviewed June 9, 2023. Accessed October 3, 2023. https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=tradename 4. Centers for Medicare & Medicaid Services. NCCI Policy Manual for Medicare: Chapter XI medicine evaluation and management services CPT codes 90000-99999 for national correct coding initiative policy manual for Medicare services. Revised January 1, 2023. Accessed October 2, 2023. https://www.cms.gov/files/document/medicaid-ncci-policy-manual-2023-chapter-11.pdf

